Drug intelligence / Profile preview

trivalent inactivated influenza vaccine (Sanofi, b283fb)

Development stage
Unknown
Lead developer
Sanofi
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Intradermal
01

Overview

Trivalent inactivated influenza vaccine (TIV) is a seasonal flu vaccine designed to protect against three different strains of the influenza virus—two subtypes of influenza A (H1N1 and H3N2) and one lineage of influenza B. It is an inactivated (killed-virus) split virion or subunit vaccine administered intramuscularly or intradermally. The standard adult dose contains 15 μg of each purified hemagglutinin antigen per strain, with higher doses available for older adults to enhance immunogenicity. TIV works by inducing an immune response against the included viral antigens, providing protection if exposed to circulating strains that match those in the formulation. The primary indication is prevention of seasonal influenza infection[5][8]. Efficacy varies by season and population but has been shown to be effective in healthy adults[1]. Multiple manufacturers worldwide produce TIV for annual vaccination campaigns.

Other names
seasonal TIVtrivalent influenza vaccineinactivated influenza vaccine (trivalent)TIV
02

Targets

HA head (Hemagglutinin globular head domain)HA stem (Influenza A hemagglutinin stem region)HA (Hemagglutinin)

Beyond the preview

Go deeper on trivalent inactivated influenza vaccine (Sanofi, b283fb).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trivalent inactivated influenza vaccine (Sanofi, b283fb).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call